Assembly Bio Q3 Loss Widens to $20.3M; Gilead $75M Fee Extends Runway Into 2029
ASMB is trading near its 52-week low of $19.2 (3.9% above the low).
Summary
Assembly Bio posted a $20.3 million Q3 loss as trial costs ramped, but the $75 million Gilead extension fee and $314.3 million cash pile push its runway into 2029 while ABI-6250 advances into Phase 2.
Key Events · Earnings and Guidance · ASMB
-
Q3 Loss Widens on Trial Costs
Net loss was $20.3 million, or $0.93 per share, versus $9.2 million, or $0.72 per share, a year earlier, driven by R&D of $20.2 million versus $16.6 million as multiple ABI-6250 studies started up.
-
$75M Gilead Fee, Runway to 2029
Received the first $75 million collaboration extension fee from Gilead in November 2026, which with $314.3 million of cash and marketable securities at September 30 is projected to fund operations into 2029; all outstanding Class B warrants from August 2025 were cancelled.
-
ABI-6250 Phase 2 Dosing Begins
Dosing started in the Phase 2 study of ABI-6250 in chronic hepatitis delta, and the FDA issued a Study May Proceed letter for a Phase 2 in PBC and PSC, expected to begin in the first quarter of 2027.
-
40% U.S. Profit Share on HSV Program
Assembly elected to share 40% of U.S. development costs and profits for the HSV helicase-primase inhibitor program with Gilead, which now leads further development of GS-1179.
Analysis · ASMB · Life Sciences
The headline loss looks bad — $20.3 million versus $9.2 million a year ago — but the quarter's real news is financial durability and pipeline progress. In November, Assembly collected the first $75 million collaboration extension fee from Gilead, which together with $314.3 million of cash and securities at September 30 funds operations into 2029. That removes any near-term financing need, a critical point for a company trading near its 52-week low. On the science side, dosing has begun in the Phase 2 hepatitis delta study of ABI-6250, the FDA cleared the company to run a Phase 2 in cholestatic liver diseases starting in the first quarter of 2027, and Assembly elected to take a 40% U.S. cost-and-profit share on the Gilead HSV program. The higher loss is mostly the cost of standing up multiple clinical trials at once, not a deterioration in the business.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASMB was trading at $19.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $410.9M. The 52-week trading range was $19.20 to $39.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.